Session 165 - 12th CROI

Home

Session 165 Poster Abstracts
HCV Co-Infection: Natural History
Wednesday, 1:30 - 3:30 pm
Hall B

947	Predictors of Liver Disease Progression in a Cohort of HIV/HCV-co-infected Drug Users Sherri O Stuver*¹, C Fleming², D Nunes^3,8, C Reed¹, S Tumilty⁴, J Murray¹, C Graham^5,7, M Koziel^5,7, D Craven⁶, P Skolnik^3,8, and C Horsburgh¹ ¹Boston Univ, MA, USA; ²Univ Coll Hosp, Galway, Ireland; ³Boston Med Ctr, MA, USA; ⁴Boston Med Ctr, MA, USA; ⁵Beth Israel Deaconess Med Ctr, Boston, MA, USA; ⁶Lahey Clin Med Ctr, Burlington, MA, USA; ⁷Harvard Med Sch, Boston, MA, USA; and ⁸Boston Univ Sch of Med, MA, USA
948	HIV Co-infection Shortens the Survival of Patients with Hepatitis C Virus-related Decompensated Cirrhosis José A García-García*¹, N Merchante¹, J Macías¹, A Arizcorreta-Yarza², J Girón-González², M Aguilar-Guisado³, R Luque³, J Ruiz-Morales⁴, M González-Serrano⁴, P Cano-Lliteras⁵, J Torre-Cisneros⁵, F Caballero-Granado⁶, E García-Chacón⁶, J Gómez-Mateos¹, and J Pineda¹ ¹Hosp Univ de Valme, Seville, Spain; ²Hosp Puerta del Mar, Cádiz, Spain; ³Hosp Virgen del Rocio, Seville, Spain; ⁴Hosp Virgen de la Victoria, Malaga, Spain; ⁵Hosp Univ Reina Sofía, Córdoba, Spain; and ⁶Hosp Punta de Europa, Cádiz, Spain
949	Neuropsychological Functioning in HCV/HIV-co-infected Subjects K Tucker¹, T Parsons¹, A Parente¹, T Dickens¹, M Fried¹, J Eron¹, K Straits-Tröster², A Tröster¹, C Hall¹, and Kevin Robertson*¹ ¹Univ of North Carolina at Chapel Hill, USA and ²Duke Univ, Durham, NC, USA
950	Hepatic Steatosis Is Associated with Dideoxynucleoside Analogue Use and HCV Genotype 3 in HIV/HCV Co-infected Patients Barbara McGovern*¹, J Ditelberg², L Taylor³, R Gandhi⁴, K Christopoulos⁴, J Fiore², F Graeme-Cook⁴, B Schwartzapfel³, S Chapman³, A M Fiorino⁵, E Rindler², P Taglienti¹, T Zaman¹, P Sax⁶, and P Hibberd² ¹Lemuel Shattuck Hosp, Jamaica Plain, MA, USA; ²Tufts-New England Med Ctr, Boston, MA, USA; ³Miriam Hosp, Providence, RI, USA; ⁴Massachusetts Gen Hosp, Boston, USA; ⁵Tufts-New England Med Ctr, Boston, MA, USA; and ⁶Brigham and Women's Hosp, Boston, MA, USA
951	Effect of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors on Liver Histology in HIV/ HCV Co-infection: Analysis of Patients Enrolled in the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT) Richard Sterling*¹, E Lissen², N Clumeck³, R Sola⁴, M Correa⁵, J Montaner⁶, M Sulkowski⁷, F Torriani⁸, D Dieterich⁹, D Messinger¹⁰, and M Nelson¹¹ ¹Virginia Commonwealth Univ Hlth System, Richmond, USA; ²Virgen del Rocío Univ Hosp, Seville, Spain; ³Ctr Hosp Univ St-Pierre, Brussels, Belgium; ⁴Hosp del Mar, Univ Autónoma de Barcelona, Spain; ⁵HCFMUSP, Casa da AIDS, Sao Paulo, Brazil; ⁶Univ of British Columbia, Vancouver, Canada; ⁷Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ⁸Univ of California, San Diego, Treatment Ctr, USA; ⁹Mt Sinai Sch of Med, New York, NY, USA; ¹⁰IST GmbH, Mannheim, Germany; and ¹¹Chelsea and Westminster Hosp, London, UK
952	Liver Histology, ART, and hyperglycemia in HIV/HCV-co-infected Adults Shruti Mehta*, D Thomas, M Torbenson, R Moore, and M Sulkowski Johns Hopkins Univ, Baltimore, MD, USA
953	1- to 3-Year Outcomes in HIV-infected Liver and Kidney Transplant Recipients Michelle Roland*¹, D Stablein², L Carlson¹, L Frasseto¹, B Murphy³, M Keller³, K Olthoff⁴, E Blumberg⁴, K Brayman⁵, R Redfield⁶, D Oldach⁶, B Barin², and P Stock¹ ¹Univ of California, San Francisco, USA; ²EMMES Corp, Rockville, MD, USA; ³Mt Sinai Sch of Med, New York, NY, USA; ⁴Univ of Pennsylvania, Philadelphia, USA; ⁵Univ of Virginia, Charlottesville, USA; and ⁶Univ of Maryland, College Park, USA
954	Evaluating the Progression of Liver Fibrosis Using Biochemical Markers in HIV/viral Hepatitis Co-infection Huda Al-Mohri*, T Murphy, and M Klein McGill Univ Hlth Ctr, Montreal, Canada